So you thought Gilead's Sovaldi was expensive? Get ready for Harvoni, the company's all-oral hep C combo regimen that won FDA approval on Friday. Cost? $94,500 for a 12-week course of treatment.
India's National Pharmaceutical Pricing Authority has fined Novartis the equivalent of $49 million for overpricing its popular pain drug Voveran, and Novartis has responded by challenging NPPA's authority to do so. The fine is just the latest move in an escalating battle between drugmakers and the NPPA.
Months after launching a regulatory battle to extend exclusivity for two of its best-selling products, Eisai won FDA approval for its Akynzeo drug to treat common side effects in patients undergoing chemotherapy.
When it comes to interactions between doctors and pharmaceutical companies, there's a growing desire for transparency among those concerned that reps influence prescribing habits. But an Australian group of doctors and academics wants to take it one step further: With an aptly titled "No Advertising Please" campaign, it's pushing to end doc-rep interactions altogether.
As Sweden's Meda wraps up its buyout of the Italian drugmaker Rottapharm, it's rolling out a rights issue--to the tune of 2 billion kronor, or about $276 million--to help finance the deal.
Turning the ancient gout remedy colchicine into an FDA-approved drug may not have been as costly an endeavor as developing a new med from scratch. But Takeda Pharmaceuticals still wants to reap brand-level sales for its version, dubbed Colcrys--and it's suing the FDA to make sure that happens.
Tuesday, two women pleaded guilty in a Polish court to handing a health fund official a trip worth more than $1,000 in exchange for backing the sale of a certain drug. And one of those women was a Novartis employee, the company said Thursday.
Did Bristol-Myers Squibb offer kickbacks and push Abilify for off-label uses? Some former sales reps-turned-whistleblowers claim it did. And given the fact that Bristol-Myers already paid $515 million to settle some off-label marketing claims related to Abilify, they say, the company violated its "we'll behave" promises to the feds.
Last October, the Pharmaceutical Research and Manufacturers of America (PhRMA) sued the federal government over a rule that allowed some hospitals to get orphan drugs at a steep discount. At first, it looked like the trade group had prevailed, because in May, a federal court struck down the authority of the U.S. Health Resources and Services Administration (HRSA) to enforce the rule.
Back in August, Impax Laboratories CEO Fred Wilkinson told investors on a conference call that the company was "well-positioned to execute on a number of transactions." And now, the company has pulled the trigger on one of those deals, spending $700 million on a pair of Pennsylvania drugmakers.
It's one step back, one step forward for AstraZeneca's key respiratory drug benralizumab.
As Big Pharma's big patent cliff took hold a few years ago, generics makers enjoyed the sales boost of one newly off-patent blockbuster after another. But savvy execs knew that the unprecedented party would end soon enough--and generics companies would be facing a sort of patent cliff of their own.
Allergan has been insisting for months that Valeant's buyout offer is "grossly inadequate" and "substantially undervalues" the company. Now that Valeant has upped its bid by $4.5 billion? Same deal, the Botox maker says, citing its own rosy earnings forecast.
The sex discrimination lawsuit against Merck lives on. A federal judge refused to toss out the $250 million suit, which claims that female sales reps were paid less, promoted less and ignored when they complained about it.
In September, Auxilium Pharmaceuticals' CEO Adrian Adams shrugged off a $2.2 billion acquisition offer from Dublin-based Endo International, saying he'd rather do a reverse merger with Canada's QLT. Endo upped its offer to $2.6 billion in cash and stock--enough to seal the deal, the company announced today.
West Pharmaceutical Services and HealthPrize Technologies are taking gamification to the next level. The companies are teaming up on a new, interactive initiative that encourages patients to take their medication and rewards them when they do.
Just as a federal judge says it's time to close the books on the Chantix litigation that's been moving through her Alabama court, Pfizer is preparing for another kind of fight over the drug. The company has been building its case for the FDA to clear the black-box warning off the stop-smoking drug's label, but patient groups are now petitioning the agency to add more heft to that warning instead.
Swiss citizens may have recently voted for some of the world's tightest controls on executive pay. But did that keep the Roche and Novartis pharma chiefs from pocketing more than 13 million Swiss francs ($13.6 million) last year? Not according to a new study.
Merck's marketing team is adding another arrow to its quiver of community-oriented campaigns: a partnership with HBCU Connect, a niche media network targeting alumni and students of historically black colleges and universities.
Six months after announcing a series of deals aimed at refocusing its R&D efforts, Novartis is starting to provide some glimpses of what the new company will look like--and who will and will not be leading it.